BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22623562)

  • 1. Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery.
    Lakhman Y; Akin O; Sohn MJ; Zheng J; Moskowitz CS; Iyer RB; Barakat RR; Sabbatini PJ; Chi DS; Hricak H
    AJR Am J Roentgenol; 2012 Jun; 198(6):1453-9. PubMed ID: 22623562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
    Chi DS; Barlin JN; Ramirez PT; Levenback CF; Mironov S; Sarasohn DM; Iyer RB; Dao F; Hricak H; Barakat RR
    Int J Gynecol Cancer; 2010 Apr; 20(3):353-7. PubMed ID: 20375796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
    Chi DS; Ramirez PT; Teitcher JB; Mironov S; Sarasohn DM; Iyer RB; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Brown CL; Aghajanian C; Gershenson DM; Hoskins WJ; Hricak H; Barakat RR
    J Clin Oncol; 2007 Nov; 25(31):4946-51. PubMed ID: 17971592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.
    Burger IA; Goldman DA; Vargas HA; Kattan MW; Yu C; Kou L; Andikyan V; Chi DS; Hricak H; Sala E
    Gynecol Oncol; 2015 Sep; 138(3):554-9. PubMed ID: 26093061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery.
    Altman AD; Nelson G; Chu P; Nation J; Ghatage P
    J Obstet Gynaecol Can; 2012 Jun; 34(6):558-566. PubMed ID: 22673172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is postoperative computed tomography evaluation a prognostic indicator in patients with optimally debulked advanced ovarian cancer?
    Lorusso D; Sarno I; Di Donato V; Palazzo A; Torrisi E; Pala L; Marchiano A; Raspagliesi F
    Oncology; 2014; 87(5):293-9. PubMed ID: 25139548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Residual Disease Status after Primary Cytoreductive Surgery in Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Carcinoma and Long-Term Progression-Free Survival].
    Otsuka I; Matsuura T
    Gan To Kagaku Ryoho; 2016 Dec; 43(13):2547-2551. PubMed ID: 28028263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of postoperative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer.
    Sala E; Mannelli L; Yamamoto K; Griffin M; Griffin N; Grant L; Parker R; Crawford R
    Int J Gynecol Cancer; 2011 Feb; 21(2):296-301. PubMed ID: 21721161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
    Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
    J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
    Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival.
    Avesani G; Arshad M; Lu H; Fotopoulou C; Cannone F; Melotti R; Aboagye E; Rockall A
    Radiol Med; 2020 Aug; 125(8):770-776. PubMed ID: 32239470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.
    Risum S; Loft A; Høgdall C; Berthelsen AK; Høgdall E; Lundvall L; Nedergaard L; Engelholm SA
    Acta Oncol; 2011 Apr; 50(3):415-9. PubMed ID: 20698810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer.
    Black D; Iasonos A; Ahmed H; Chi DS; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2007 Oct; 107(1):66-70. PubMed ID: 17614125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
    Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
    Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.